<DOC>
	<DOCNO>NCT00122486</DOCNO>
	<brief_summary>This Phase 2 study involve tenofovir disoproxil fumarate ( TDF ) ass extend safety TDF 300 mg per day among young woman HIV-infected .</brief_summary>
	<brief_title>Study Tenofovir Disoproxil Fumarate ( TDF ) Prevention HIV</brief_title>
	<detailed_description>The protocol describe randomize , fully-masked , parallel , placebo-controlled study TDF pre-exposure prophylaxis HIV high-risk woman . TDF select investigation prophylaxis HIV high-risk woman unique pharmacological profile . In addition convenience daily single tablet , TDF ’ safety profile comparable placebo among HIV infect person , strike anti-HIV potency , low potential selection resistant virus . TDF clear body kidney metabolize liver . Therefore , TDF limit potential pharmacokinetic interaction hepatically metabolize drug . Each property necessary give reality intend target population . Moreover , initial prevention study simian model provide encouraging result . Finally , drug ’ sponsor supportive investigate potential use TDF preventive , well therapeutic agent . Participants ’ HIV status monitor monthly . Participants also monitor safety use periodic physical examination , serial laboratory test adverse event query . Lab test kidney liver function conduct screening , month 1 , 3 every 3 month thereafter final visit early withdrawal . To minimize risk contract HIV infection , participant counsel monthly use male condom act intercourse . Participants convert antibody HIV counsel refer medical service appropriate country .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV seronegative Willing able give inform consent 18 year 35 year old , inclusive Sexually active ( average , coitus 3 time per week ) Have three sexual partner last month Willing use study product direct Willing adhere followup schedule Willing participate study 12 month Not pregnant , breast feeding , desire pregnancy 12 month participation Have adequate renal function ( serum creatinine &lt; 1.5 mg/dL ) Have adequate liver function ( hepatic transaminase [ ALT AST ] &lt; 43 U/L ) Have adequate serum phosphorus ( great equal 2.2 mg/dL ) In general good health ( active , serious infection require parenteral antibiotic ; active clinically significant medical condition , include heart disease , diabetes , asthma , alcoholism , cancer )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>AE adverse event</keyword>
	<keyword>AIDS acquire immunodeficiency syndrome</keyword>
	<keyword>ALT ( SGPT ) alanine aminotransferase</keyword>
	<keyword>ART antiretroviral therapy</keyword>
	<keyword>AST ( SGOT ) aspartate aminotransferase</keyword>
	<keyword>DCF data collection form</keyword>
	<keyword>DMC Data Monitoring Committee</keyword>
	<keyword>FDA ( U.S. ) Food Drug Administration</keyword>
	<keyword>GCP Good Clinical Practice guideline</keyword>
	<keyword>HB sAg Hepatitis B surface antigen</keyword>
	<keyword>ICH International Conference Harmonisation</keyword>
	<keyword>IND Investigational New Drug Application</keyword>
	<keyword>IRB Institutional Review Board</keyword>
	<keyword>IU international unit</keyword>
	<keyword>mg milligram ( )</keyword>
	<keyword>mm3 cubic millimeter ( )</keyword>
	<keyword>PCR polymerase chain reaction</keyword>
	<keyword>SAE serious adverse event</keyword>
	<keyword>µg microgram</keyword>
	<keyword>ULN upper limit normal range</keyword>
	<keyword>WB Western Blot</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>